24 & 25 juin 2010
Les conférences auront lieu
au Musée d’Art Moderne
Les Abattoirs
76 Allée Charles De Fitte
Toulouse
Toulouse
Novel targeting drugs and Radiotherapy
France
from the bench to the clinic
Vendredi 25 juin 2010
| 08h30 |
Séance plénière : Cellules souches et radiothérapie | ||
| 08h30 |
Michael Clarke, Directeur adjoint de l’Institut de Stanford, de cellules souches et médecine régénératrice, Stanford School of Medecine, États-Unis "Clinical Implications of Cancer Stem Cells" |
|
|
| 09h15 |
Jeremy Rich, Président Département de biologie des cellules souches et la médecine régénérative, Clinique de Cleveland, Etats-Unis “An Evolving View of Cancer Stem Cells in Brain Tumor Biology” | ||
| 10h00 |
Frank Pajonk, Département de radio-oncologie, UCLA, USA "Illuminating the Seed Instead of the Soil:Imaging of Cancer Stem Cells” | ||
| |
|||
| 10h45 - 11h00 |
Pause café | ||
| |
|||
| 11h00 - 12h15 |
Communications orales |
• Ira Skvortsova : Putative determinants of EGFR inhibitors-induced enhancement of squamous cell carcinoma radioresponse.
• Shuraila Zerp : APO866, an NAD+ depleting agent combined with PARP inhibitor, Olaparib, shows enhanced radiation-induced apoptosis and radiosensitization.
• James Welsh : A Phase II Study to Determine the Efficacy of Tarceva (Erlotinib Hydrochloride) with Concurrent Whole Brain Radiation Therapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer.
• Emmanuel Chautard : Akt signaling pathway : a target for radiosensitizing human malignant glioma.
• Stéphane Supiot : NVP-BEZ235, a Novel Dual Pan-class I PI3K and mTOR Kinase Inhibitor, Radiosensitizes Prostate Cancer Cell Lines Independent of PTEN in vitro.
| |
|||
| 12h15 |
Déjeuner | ||
| |
|||
| 13h00 |
Symposium Schering Plough : "Current trends in research and treatment of brain tumors" Michael Weller, Département de neurologie - CHU de Zurich - Suisse Long-term survival analysis of EORTC NCIC clinical Trials Wolfgang Wick, Département de neuro-oncologie - Université de Heidelberg - Allemagne) Dose-dense : Is it the wave of the future ? Antoine Carpentier, Département de neurologie - Hôpital Avicenne Paris, France Molecular biology and targeted therapies |
|
|
| 13h00 |
Séance plénière : Hypoxie | ||
| 14h00 |
Amato J. Giaccia, Département de Radiation Oncologie, Stanford School of Medecine, États-Unis "Synthetic Lethality and Cancer Therapy" | ||
| 14h45 |
Brad Wouters,, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada "Regulation of autophagy during hypoxia by the unfolded protein response" | ||
| |
|||
| 15h30 - 16h30 |
Communications orales |
• François Paris Rho A GTPase regulates endothelial cell response to ionizing radiation.
• Solea Ken Assessment of pre and post-radiotherapy perfusion of glioblastoma : a longitudinal study with H215O PET and DCE-MRI.
• Anne Laprie Evaluation of predictive indexes in radiotherapy of glioblastoma : comparison of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and magnetic resonance spectroscopy imaging (MRSI).
• Aleck Hercbergs Radiosensitization of H522 Lung Cancer Cells by Nanoparticulate Tetraiodothyroacetic Acid.
• Laurence Maggiorella NBTXR3 nanoparticles induce marked radio-enhancement and tumor response in human fibrosarcoma and liposarcoma models.
| |
|
| 16h30 |
Clôture |
